140
Participants
Start Date
March 12, 2021
Primary Completion Date
April 7, 2027
Study Completion Date
October 5, 2027
Teclistamab
Participants will receive teclistamab.
Daratumumab
Participants will receive daratumumab.
Pomalidomide
Participants will receive pomalidomide.
Lenalidomide
Participants will receive lenalidomide.
Bortezomib
Participants will receive bortezomib.
Nirogacestat
Participants will receive nirogacestat.
Calvary Mater Newcastle Hospital, Waratah
UZA, Edegem
Alfred Health, Melbourne
St Vincents Hospital Melbourne, Fitzroy
UZ Gent, Ghent
Memorial Sloan-Kettering Cancer Center, New York
Weill Cornell Medical College, New York
University of Pittsburgh Medical Center, Pittsburgh
Levine Cancer Institute, Charlotte
Emory University, Atlanta
Institut Universitaire du cancer de Toulouse-Oncopole, Toulouse
CHU de Bordeaux - Hospital Haut-Leveque, Pessac
Chu Rennes Hopital Pontchaillou, Rennes
University of Alabama at Birmingham, Birmingham
Tennessee Oncology, Nashville
CHU Nantes, Nantes
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
Medical College Of Wisconsin, Milwaukee
Centre Leon Berard, Lyon
Colorado Blood Cancer Institute, Denver
University of California San Francisco, San Francisco
Seattle Cancer Care Alliance, Seattle
Washington University School Of Medicine, St Louis
Hackensack University Medical Center, Hackensack
University College Hospital, London
The Christie Nhs Foundation Trust, Manchester
The Royal Marsden NHS Trust Sutton, Surrey
Janssen Research & Development, LLC
INDUSTRY